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Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) is an autosomal-dominant cancer-predisposition syndrome
with a significant risk of gastric, but not colorectal, adenocarcinoma. Wemapped the gene to 5q22 and found loss of the wild-type allele
on 5q in fundic gland polyps from affected individuals. Whole-exome and -genome sequencing failed to find causal mutations but,
through Sanger sequencing, we identified point mutations in APC promoter 1B that co-segregated with disease in all six families. The
mutations reduced binding of the YY1 transcription factor and impaired activity of the APC promoter 1B in luciferase assays. Analysis
of blood and saliva from carriers showed allelic imbalance of APC, suggesting that these mutations lead to decreased allele-specific
expression in vivo. Similar mutations in APC promoter 1B occur in rare families with familial adenomatous polyposis (FAP). Promoter
1A is methylated in GAPPS and sporadic FGPs and in normal stomach, which suggests that 1B transcripts are more important than 1A in
gastricmucosa. Thismight explain why all knownGAPPS-affected families carry promoter 1B pointmutations but only rare FAP-affected
families carry similar mutations, the colonic cells usually being protected by the expression of the 1A isoform. Gastric polyposis and
cancer have been previously described in some FAP-affected individuals with large deletions around promoter 1B. Our finding that
GAPPS is caused by point mutations in the same promoter suggests that families with mutations affecting the promoter 1B are at risk
of gastric adenocarcinoma, regardless of whether or not colorectal polyps are present.Introduction
One of the key features of gastric adenocarcinoma and
proximal polyposis of the stomach (GAPPS) is a carpeting
of more than 100 fundic gland polyps (FGPs) in the oxy-
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cinomas. Sporadic FGPs are identified in ~5% of individ-
uals undergoing upper gastrointestinal endoscopy6–8 and
might be more common in individuals who have received
proton pump inhibitor therapy.9–11
The gastric antrum, pylorus, small intestine, and colon
were all reported to be normal in the original GAPPS-
affected families,1 highlighting a clear difference between
this condition and familial adenomatous polyposis
(FAP [MIM: 175100]) syndrome. FAP12–16 and attenuated
FAP17 (AFAP) are autosomal-dominant conditions charac-
terized by the development of multiple adenomatous
polyps in the colorectum as well as extra-colonic manifes-
tations, due to germline coding mutations or large dele-
tions or duplications in APC (MIM: 622731) (adenomatous
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(foveolar) phenotype in 92% of the case subjects.20 There
are occasional reports of gastric adenocarcinoma arising
from FGPs in individuals with FAP.21–23
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The AmFGPs,25 whereas FAP-associated FGPs frequently harbor
somatic coding APC gene mutations. However, sporadic
FGPs with low-grade dysplasia are molecularly more
similar to FAP-associated FGPs in the type and frequency
of APC alterations than to the sporadic FGPs without
dysplasia.26 The distribution of somatic mutations of
APC in colorectal adenomas is non-random and partly
related to the site of the germline mutation but differs
from the non-random pattern in duodenal and fundic
gland polyps.27,28
Here we report three different point mutations in the
promoter 1B of APC that are responsible for GAPPS in
all six families. We also demonstrate that these muta-
tions are located within a Ying Yang 1 (YY1) binding
motif and reduce the expression from the promoter 1B
by interrupting YY1 binding. Additionally, we report
that rare families with extensive FGPs, but with a more
classical FAP presentation in the colon, harbor one of
two point mutations in the same YY1 binding site in pro-
moter 1B.Subjects and Methods
GAPPS-Affected Families
We identified one Australian (family 1) and five North American
(families 2–6) families that meet the diagnostic criteria for
GAPPS,1 by means of autosomal-dominant transmission of
numerous, predominantly fundic gland, gastric polyps restricted
to the body and fundus with regions of dysplasia or gastric adeno-
carcinoma, and no evidence of colorectal or duodenal polyposis
(Figure 1). Families 1–3 were described previously,1 but at that
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Figure 1. GAPPS Pedigrees
Abbreviations are as follows: POSITIVE/neg, APC promoter 1B mutation status by Sanger sequencing; WES, whole-exome sequencing;
WGS, whole-genome sequencing by HiSeq or Complete Genomics; WGS-X Ten, whole-genome sequencing by X Ten. Only affected in-
dividuals and carriers are shown.
(A) Family 1. Individuals and clinical presentation are as follows: I-4, unconfirmed gastric cancer; II-2, normal endoscopy aged 72
years; II-4, normal endoscopy aged 77 years; II-6, no endoscopy; II-11, normal endoscopy aged 68 years; III-33, normal endoscopy
aged 60 years; IV-24, normal endoscopy aged 42 years. Thirty or fewer fundic gland polyps were observed in these non-carriers:
III-22, 17 FGPs; III-23, 15 FGPs; IV-13, 30 FGPs; III-21, 7 FGPs; III-25, 25 FGPs. In two polyps from individuals III-7 and IV-4 where
parental origin could be evaluated, the wild-type haplotype was lost. Asterisk (*) indicates sample was included in the linkage
analysis.
(B) Family 2. I-4, non-melanoma skin cancer, unconfirmed colon or gastric cancer; III-21, thyroid cancer (and fundic gland polyposis).
(C) Family 3. I-2, leukemia; I-3, brain cancer; I-5, antral gastric cancer, no gastric polyps; I-6, prostate cancer; I-7, lung cancer.
(D) Family 4.
(E) Family 5.
(F) Family 6. II-1, prostate cancer; II-2, ovarian cancer and unconfirmed colon cancer; II-3, unconfirmed colon cancer; III-1, unconfirmed
colon cancer; IV-21, bone cancer, gastro-intestinal cancer.However, more detailed phenotyping found that she has fewer
than 30 FGPs with no evidence of dysplasia and is therefore now
considered unaffected (Figure S1). Since our previous publication,
I-5 in family 3 has developed gastric cancer. In family 4, which had
no case of gastric adenocarcinoma, at least one fundic gland polyp832 The American Journal of Human Genetics 98, 830–842, May 5, 2analyzed by a gastrointestinal pathologist (F.C.) contained areas of
low-grade dysplasia with some focal high-grade dysplasia. All
subjects included in this analysis were of European descent and
provided written informed consent as well as data and blood sam-
ples under ethically approved protocols.016
Linkage Analysis
We performed linkage analysis of family 1 using 39 germline DNA
samples available at the time with the Human Linkage-12 SNP
panel (Illumina; 6,090 SNPs) according to the manufacturer’s pro-
tocol. We carried out linkage analyses using an affected-only Mar-
kov chain-Monte Carlomethod (LNMARKERS)29 modeling GAPPS
as an autosomal-dominant trait with an allele frequency of 0.001
and a penetrance of 80%. Only case subjects with florid gastric
polyposis verified by endoscopy were included as affected.
Next-Generation Sequencing
We carried out whole-exome sequencing (WES) in 19 members of
families 1–5 (Figure 1) using Agilent SureSelect and/or Illumina
TruSeq Exome Enrichment kit, followed by 75 bp or 100 bp
paired-end sequencing on Illumina HiSeq (Table S1). We obtained
whole-genome sequencing (WGS) data on the Illumina HiSeq
platform from four case subjects of families 1 and 2 andwith Com-
plete Genomics for additional members of family 2 (Figure 1). We
also performed WGS with the Illumina X Ten platform for seven
fundic gland polyps from family 1, with the matching germline
DNA. We carried out sequence alignment, with BWA,30 and
variant calling for SNVs via GATK31 and qSNP32 and small inser-
tion and deletions via pindel.33 We validated rare variants of
interest and, for those identified in family 1, established their
frequency in a panel of 369 Australian controls, by iPLEX genotyp-
ing34 on theMassARRAY system (Agena Bioscience) (primers avail-
able on request).
Copy-Number Analysis
Fourteen fundic gland polyps from six members of family 1 were
obtained during gastrectomies and snap frozen. ‘‘Book end’’ sec-
tions stained with hematoxylin and eosin (H&E) were reviewed
by a gastrointestinal pathologist (M.B.) to estimate the percentage
of FGP. Only sections estimated to contain at least 70% FGP were
subjected to DNA extraction via the QIAamp DNA Micro kit
(QIAGEN). FGP DNA was hybridized to the Illumina Human
Omni2.5-8 v1.1 SNP arrays. Copy-number changes were called
with the Genome Alteration Print (GAP) tool35 and copy number,
B allele frequency, and LogR ratio was visualized with Circos.36 In
order to determine which allele was lost, we used 55 SNPs in the
region that we could phase because they were heterozygous in in-
dividuals III-7 and IV-4 but homozygous in other family
members.
Sanger Sequencing of APC Promoter 1B
The APC promoter 1B was amplified by AmpliTaq Gold polymer-
ase (Life Technologies) using Touchdown-PCR with the following
conditions: 94C for 12min, 94C for 30 s, 68C for 30 s in the first
cycle and the anneal temperature deceased 1C per cycle, 72C
for 30 s; after 12 cycles conditions changed to 94C for 30 s,
55C for 30 s, 72C for 30 s for another 25 cycles, final extension
of 72C for 7 min. The PCR product was sequenced using BigDye
Terminator v.3.1 (Life Technologies) according to the standard
protocol. Primers are listed in Table S2.
Gastric Carcinoma Samples
As part of a prospectively collected cohort of sporadic gastric ade-
nocarcinomas, we tested a subgroup of 26 cases of gastric adeno-
carcinoma comprising 13 diffuse gastric cancers, 12 intestinal
gastric cancers, and 1 mixed gastric cancer as classified by Lau-
ren37 for mutations in the APC promoter 1B. For each sample,The Am10 mM sections were macrodissected to increase tumor purity
and DNA extracted with the DNA QIAamp DNA Mini kit
(QIAGEN). DNA was extracted from blood samples via the salt
extraction method to obtain matched germline DNA.
Plasmid Generation
A 500 bp fragment (chr5: 112,042,880–112,043,379) containing
part of the APC promoter 1B region (GenBank: D13981.1) was
amplified from genomic DNA of affected individuals from families
1, 2, and 3. To separate c.195A>C and c.125delA, which
co-segregate in family 1, we designed two sets of mutagenic
oligonucleotides for each allele of c.195A>C. After the first
PCR step, two fragments overlapping by 20 bases were fused
together by an overlapping extension PCR. DNA fragments
containing c.195A>C plus c.125delA, c.195A>C alone,
c.125delA alone, c.191T>C and c.192A>G, or wild-type
sequence were subsequently cloned into the pGL3 basic luciferase
reporter construct. PCR primers are listed in Table S2.
Reporter Assays
Cell lines were maintained under standard conditions, routinely
tested for Mycoplasma, and identity profiled with short tandem
repeat markers. AGS and MKN74 were provided by Dr. Andrew
Giraud and HCT116 and RKO by Dr. Vicki Whitehall. Two
gastric carcinoma cell lines, MKN74 and AGS, and two colorectal
cancer cell lines, HCT116 and RKO, were transiently transfected
with equimolar amounts of luciferase reporter constructs using
Renilla luciferase as an internal control reporter. Luciferase activ-
ity was measured 24 hr after transfection using Dual-Glo Lucif-
erase (Promega). Firefly luciferase activity was normalized to
Renilla luciferase, and the activity of each mutant construct
was measured relative to wild-type construct, which had a
defined activity of 1. Expression differences were assessed by
log transforming the data and performing two-way ANOVA, fol-
lowed by Dunnett’s multiple comparisons test; for ease of inter-
pretation, values were back-transformed to the original scale for
the graphs.
Electrophoretic Mobility Shift Assay
Nuclear lysates were extracted from a gastric and colorectal cancer
cell line (AGS and RKO, respectively) as described previously.38
EMSAs were carried out with the Lightshift Chemiluminescent
EMSA Kit (Thermo Scientific). Oligonucleotide sequences used in
the assays are listed in Table S2. Competitor oligonucleotides
were used at 10-, 30-, and 100-fold molar excess. For gel-supershift
assays, 5 mg of rabbit polyclonal YY1 antibody (Santa Cruz cat# sc-
1703; RRID: AB_2218501) was added immediately before probe
addition. The rabbit pre-immune IgG (Santa Cruz cat# sc-2027;
RRID_AB_737197) was used as a negative control.
Chromatin Immunoprecipitation
YY1 ChIP-qPCR (YY1; Santa Cruz cat# sc-1703; RRID:
AB_2218501) assays were conducted as described previously39
with a sheared fragment size of 300 bp to 1 kb. For qPCR, 1 mL
from 30 mL of immunoprecipitated DNA extract was used. Primers
are listed in Table S2.
APC Allelic Imbalance Analysis
We obtained fresh blood samples in PAXgene Blood RNA tubes
(QIAGEN) from two affected and one unaffected mutation carriers
and from two unaffected control subjects (who did not carry theerican Journal of Human Genetics 98, 830–842, May 5, 2016 833
c.195A>C mutation) from family 1 whom we had found by
iPLEX to be heterozygous for an APC 30 UTR SNP rs448475. RNA
was extracted via the PAXgene Blood miRNA kit (QIAGEN).
cDNA was transcribed via Superscript III Reverse Transcriptase
(Life Technologies) and Sanger sequenced to look for allelic imbal-
ance at rs448475 (primer sequences in Table S2).
APC allelic imbalance assays were also performed on GAPPS-
affected family 3 and the FAP-affected family. Both DNA and
RNA were isolated from saliva obtained from two members of
family 3 (II-3 and II-4) and an affected carrier from the FAP family
(III-2) using Oragene DNA and RNA kits, respectively (DNA Geno-
tek). cDNA was generated with Superscript III Reverse Transcrip-
tase (Life Technologies). For family 3, genomic DNA and cDNA
were Sanger sequenced at seven SNP sites (rs2229992, rs351771,
rs41115, rs43437, rs866006, rs459552, and rs465899) in exons
10, 12, and 14 of APC. However, only rs2229992 was informative
across both individuals II-2 and II-3. For the FAP-affected family,
we used the expressed promoter variant, c.190G>A, in an
affected carrier (III-2) to assess allelic imbalance. Allelic imbalance
was assessed by comparing cDNA and genomic DNA sequence
traces (primer sequences in Table S2).
We isolated gDNA and RNA from cryostored normal stomach
and FGP-positive samples from family 1 individuals using the
TissueLyser and AllPrep DNA/RNA Mini Kit (QIAGEN), including
DNase treatment step to remove gDNA contamination of RNA.
cDNA was transcribed with Superscript IV Reverse Transcriptase
(Life Technologies) and Sanger sequenced to look for allelic im-
balance of transcribed c.195A>C mutation (primer sequences
in Table S2). Controls with no reverse transcriptase added were
negative, indicating no gDNA contamination of RNA/cDNA.
gDNA and RNA was also isolated from a cryostored FGP sample
from individual II-3 in family 3 via the DNeasy Blood and Tissue
Kit (QIAGEN) and miRNeasy Mini Kit (QIAGEN). cDNA was tran-
scribed with Superscript III Reverse Transcriptase (Life Technolo-
gies) and Sanger sequenced to look for allelic imbalance of the
c.192A>G mutation (primer sequences in Table S2).Results
We have identified six families affected by GAPPS
(Figure 1).Linkage Analysis
Linkage analysis in 39 members of family 1 (Figure 1A)
mapped the GAPPS mutation to a 46 Mb region on
chromosome 5 (chr5: 75,947,905–121,407,036) with a
maximum LOD score of 4.51.Whole-Exome and -Genome Sequencing
Whole-exome sequencing (WES) in 15 affected and 4 unaf-
fected members of families 1–5 (Table S1) failed to identify
any genes in the linked region of chromosome 5 with
novel or rare (minor allele frequency < 0.001) missense,
splice site, or coding indel mutations that co-segregated
with disease in all families. Furthermore, although the
mean coverage ranged from 58- to 68-fold, no novel or
rare coding mutations were shared between affected mem-
bers of family 1. In the smaller families in which closely
related individuals were sequenced, we found multiple834 The American Journal of Human Genetics 98, 830–842, May 5, 2shared coding variants throughout the genome. We also
carried out whole-genome sequencing (WGS) to a mean
coverage of 17- to 75-fold in two affected members of
family 1 and five affected members and three unaffected
members, including a spouse, from family 2. This did not
identify any novel non-coding variants in the linkage re-
gion shared between all affected case subjects from both
families. However, we did find 202 putative non-coding
variants shared between both sequenced members of fam-
ily 1. Of these, the majority were calls of low confidence
but 67 were worthy of follow up and amenable to iPLEX
design. We genotyped 63 family members and 369 Austra-
lian control subjects. Sixteen variants were not validated
and 18 did not co-segregate with affected status or were
present in control subjects, but the remaining 33 variants
did co-segregate and further defined the linkage region to
14.3 Mb (chr5: 107,080,146–121,407,036). None of these
variants were in obvious regulatory regions as indicated
by ENCODE, Roadmap, or FANTOM5 (see Web Resources)
or in previously unannotated genes (using the latest
version of GENCODE). We also found 42 non-coding var-
iants shared between the five affectedmembers of family 2,
but none were close to the non-coding variants found in
family 1 (the closest from the two families were 433 bp
apart). Refiltering against dbSNP142 reduced the number
of variants in family 1 and family 2 to 22 and 30, respec-
tively (Table S3).
Given reports of germline and somatic LINE-1 retro-
transposition in gastrointestinal tumors,40,41 including in
the chr5 linkage region,42,43 we also analyzed the WGS
data with a bioinformatic strategy geared specifically to-
ward discovery of novel retrotransposition insertions.43
However, no new polymorphic LINE-1 insertions were
found. We used cnvHitSeq44 to identify copy-number
changes in this region from the WGS Hi-Seq data from
two affected members of family 1. cnvHitSeq integrates
read-depth and paired-end information to genotype
copy-number changes. We identified three heterozygous
deletions and one heterozygous duplication shared be-
tween these two samples in this region (Table S4). Two of
these CNVs do not overlap any reported in the Database
of Genomic Variants,45 but neither of them overlapped
exons.
Loss of Heterozygosity Analysis
Having failed to find a convincing causal mutation byWES
and WGS, we then carried out copy-number analysis in
FGPs from family 1 to determine whether there was any
loss of heterozygosity (LOH) in the linkage region, which
would be consistent with an inheritedmutation in a tumor
suppressor gene and a somatic mutation by allelic loss. We
identified LOH, only on chromosome 5, in 6/14 FGPs (Fig-
ures 2 and S2). In the two polyps from individuals III-7 and
IV-4 with the clearest LOH where parental origin could be
evaluated, the wild-type haplotype was lost. The 12.7 Mb
region overlapping the linkage region contained APC as
well as 45 other coding genes.016
Figure 2. Genomic Copy-Number Changes of Six Gastric Fundic Gland Polyps
Whole-genome copy-number plots from copy-number analysis of each polyp represented by log R ratio and B allele frequency. Deviation
of B allele frequency suggests allelic imbalances and copy-number variation at 5q. Genomic SNP data of the remaining eight polyps
showing no LOH are presented in Figure S2.Sanger Sequencing
Protein truncating and large deletion mutations of APC
cause familial adenomatous polyposis (FAP). Notwith-
standing their different colonic involvement, GAPPS
and FAP have similar gastric phenotypes of polyposis
and predisposition to carcinoma. We therefore looked
for allelic imbalance (AI) in the expression of APC in
blood from affected members of family 1 as an indicator
of an inherited regulatory mutation (described below).
In seeking an informative polymorphism for AI analysis,
we Sanger sequenced the two discrete APC promoters
(Figure 3). Sequencing identified two mutations (a point
mutation, chr5: 112,043,220 A/C; c.195A>C, and a
1-bp deletion, chr5: 112,043,290 A/; c.125delA) in pro-
moter 1B that completely co-segregated with GAPPS in all
27 affected members of family 1 from which we had
blood samples (Figures 1, S3A, S3B, S3E, and S3F). These
variants are in close proximity to a variant identified in
family 2 by Complete Genomics (chr5: 112,043,224
T/C; c.191T>C) (Table S3). Additional sequencing of
promoter 1B revealed this mutation (chr5: 112,043,224
T/C; c.191T>C) in all the affected members of families
2, 4, 5, and 6 (Figures 1, S3A, and S3C) and another
(chr5: 112,043,223 A/G; c.192A>G) in both affected
members of family 3 (Figures 1, S3A, and S3D). These
three mutations were not reported in any public data-
bases, including 2,598 samples from 1000 Genomes,51
nor are they present in 344 germline samples from our
in-house WGS cancer projects,52–54 nor did we find any
c.195A>C carriers in 2,326 Australian control samples
genotyped by iPLEX. We genotyped 20/30 of the rareThe Amnon-coding variants identified in family 2 in families
4–6 and found that family 4 carried the same rare variants
from chr5: 108,498,647 to chr5: 115,074,561 (Table S3),
suggesting that they share a common ancestor.
Re-exploration of previously reported FAP-affected fam-
ilies55 revealed that the single mutation reported in
affected probands from eight probably related families
from the same region of France, g.20377206A>T, is by
more recent nomenclature a different base substitution
(c.192A>T) at the same nucleotide that is mutated in
family 3 (c.192A>G). Although FGPs are prominent in
these families, all probands and many family members
have had colectomies for florid colonic polyposis. At the
same time, a family with five affected persons with profuse
FGPs and a variable onset of colorectal polyposis, resulting
in colectomy in all mutation carriers between the ages of
4 and 57 (Figure S4), was found to carry a c.190G>A mu-
tation in promoter 1B.
Somatic Mutations and Methylation
We carried out additional WGS of seven FGPs without LOH
(Figure S2), with their matching germline DNAs, in family
1 (using Illumina’s X Ten platform). This experiment, initi-
ated before we found the germline promoter 1B mutations,
confirmed the results of Sanger sequencing (Figure S5). In
the region of linkage/LOH, we also found four somatic
truncating mutations of APC—c.637C>T (p.Arg213Ter)
(GenBank: NM_001127510, NP_001120982), c.1690C>T
(p.Arg564Ter), c.6096_6102delTGACTCT (p.Ile2032Metfs*
10), and c.4393_4394delAG (p.Ser1465Trpfs*3)—at esti-
mated mutant allele frequencies of 31%, 9%, 8%, and 12%,erican Journal of Human Genetics 98, 830–842, May 5, 2016 835
Figure 3. Schematic of the APC 1A and 1B Promoters Showing the Location of Deletions Described in FAP and Point Mutations
in GAPPS
Black bars denote large deletions in FAP-affected families reported by Pavicic et al.,46 Rohlin et al.,47 Snowet al.,48 Kadiyska et al.,49 andLin
et al.50 ‘‘RefSeq Genes’’ track shows APC 1A transcripts (GenBank: NM_000038 and NM_001127510) and APC 1B transcript (GenBank:
NM_001127511). Bottom part depicts the sizes of two promoters, the distance in between, and point mutations in the families.respectively, in FGPs. Three of the somatic mutations were
confirmed by iPLEX (Figure S6), but we could not design
iPLEX primers for p.Ser1465Trpfs*3. No rare or novel germ-
line codingmutations in the linkage/LOH region were iden-
tified by this additional X Ten WGS, nor did we find any
mutations in CTNNB1 that are characteristic of sporadic
FGPs.25 After microdissection to achieve >90% neoplasia
in the sections used for DNA isolation, we sequenced the
APC promoter 1B in 26 sporadic gastric cancer (GC) cases
(including 13 diffuse, 12 intestinal, and 1 mixed-type GC)
with their matching germline DNAs but found no germline
or somatic mutations.
Sequencing the canonical exon 3 CTNNB1 hotspot
mutations in two FGPs from individual II-4 of family 3
(a non-carrier of the familial promoter mutation) and
seven sporadic FGPs from five individuals revealed hotspot
mutations in both polyps from II-4 and in three of the spo-
radic polyps (Figure S7). This is in contrast to absence of
CTNNB1 hotspot mutations in 11 FGPs from 5 carriers of
promoter mutations in family 1 (data not shown).
Methylation of APC promoter 1A was demonstrated in
both normal stomach and FGPs of carriers and non-carriers
within GAPPS-affected families and in sporadic FGPs and
matched normal stomach (Table S5).
Functional Analysis of 1B Promoter Mutations
Transcriptional factor binding site (TFBS) search tools56,57
predicted Yin Yang 1 (YY1) binding to the chr5:
112,043,220–112,043,224 region of promoter 1B, which
JASPAR58 analysis predicted would be disrupted by the
three GAPPS and two FAP mutations (Figure 4A). Via chro-
matin immunoprecipitation (ChIP), we showed that YY1
binds this site in two gastric cancer cell lines (AGS and
MKN74 cells) and two colorectal cancer lines (HCT116
and RKO) (Figures 4B and S8). Using electrophoretic
mobility shift assays (EMSAs), we showed that the mutant
alleles of GAPPS mutations (c.191T>C, c.192A>G, and
c.195A>C) and the FAP mutations (c.190G>A and
c.192A>T) disrupted protein binding to the region in
both AGS and RKO cells (Figures 4C and 4D). Furthermore,
EMSAs using anti-YY1 antiserum or a YY1 consensus oligo-836 The American Journal of Human Genetics 98, 830–842, May 5, 2nucleotide competitor suggested that the protein disrupted
by themutant alleles is likely to be YY1 (Figures 4E and S9).
Luciferase reporter assays demonstrated that constructs
containing c.195A>C plus c.125delA, c.195A>C
alone, c.191T>C, and c.192A>G showed significantly
decreased activity compared to the wild-type construct in
MKN74, AGS, and RKO cells (Figures 5 and S10). In addi-
tion, the construct containing both c.195A>C and
c.125delA showed reduced expression in HCT116 colo-
rectal cancer cell line. The c.125delA variant alone only
showed significantly decreased activity in RKO and
HCT116 cells (Figure S10).
Allelic Imbalance
Having found the 1B promoter mutations, we looked for
allele imbalance (AI) of the 1B APC isoform. Promoter 1B
transcripts are typically 100- to 1,000-fold more highly ex-
pressed than promoter 1A transcripts in blood,47 and we
inferred that this might extend to transcripts derived
from saliva samples because DNA from saliva is mainly
derived from lymphocytes.59 We therefore used blood
from family 1 and saliva from GAPPS-affected family 3
and from the FAP-affected family carrying the
c.190G>A mutation for AI analysis of carriers and non-
carriers. There are no informative polymorphisms specific
to APC 1B transcripts, so we genotyped a common SNP,
rs448475, in 70 family members to determine which allele
was in cis with mutation in each individual. We used
rs448475 as the marker for allelic imbalance in family 1
because it was heterozygous in multiple affected and unaf-
fectedmembers and is in the 30 UTR of both transcripts.We
obtained fresh blood from two affected carriers, one unaf-
fected mutation carrier, and two unaffected controls (who
did not carry the affected haplotype) from family 1, all of
whom were heterozygous for rs448475. cDNA sequencing
showed AI in the three mutation carriers, with reduced
expression of the G allele that was carried on the affected
haplotype (Figure 6A). We sequenced seven SNPs in exons
10, 12, and 14 of APC in family 3 to look for AI; rs2229992
was the only informative SNP across both individuals II-3
and II-4. We found AI in individual II-3, who harbors the016
Figure 4. GAPPS and FAPMutations Alter
YY1 Binding to the APC Promoter 1B





(g.112043225A) in the APC promoter 1B
are predicted to disrupt YY1 binding at
positions 1, 4, 5, and 6, respectively.
(B) ChIP-qPCR on the APC promoter 1B
region in AGS and MKN74 cells. ChIP as-
says were performed with a YY1 antibody
or IgG control antibody on the region of
1B containing the predicted YY1 binding
site. A negative control region was used to
represent nonspecific binding. One of two
biological replicates is shown. Error bars
denote SD.
(C and D) EMSA of promoter 1B using with
a biotinylated DNA duplex representing
the predicted YY1 binding region with
and without (WT) GAPPS mutations
c.195A>C, c.192A>G, and c.191T>C
(C) and FAP mutations c.190G>A and
c.192A>T (D).
(E) EMSA-supershift using the WT DNA
duplex and a polyclonal antibody against
YY1 with AGS nuclear extracts. Rabbit IgG
was used as a negative control. The black
arrowhead denotes the YY1 supershifted
complex.promoter c.192A>G variant, but not in II-4, who is a
non-carrier of this mutation (Figure 6B). AI was also
observed in saliva from an affected carrier, III-2, of the
FAP family, using the promoter c.190G>A mutationThe Am(Figure S11). We also looked for AI in normal stomach
and FGPs from five affected carriers from family 1 and in
the FGP of an affected carrier of family 3, using the
c.195A>C and c.192G>A mutations, respectively,Figure 5. Mutations in APC Promoter 1B
Show Decreased Transcriptional Activity
in Gastric Carcinoma Cell Lines AGS and
MKN74 and Colorectal Cancer Cell Lines
HCT116 and RKO
Error bars denote 95% confidence intervals
from three independent experiments
performed in triplicate. p values were
determined by two-way ANOVA followed
by Dunnett’s multiple comparisons test
(**p < 0.01, ***p < 0.001, ****p < 0.0001
compared to wild-type pGL3-APC 1B
construct) on log transformed data; for
ease of interpretation, back-transformed
data have been graphed.
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Figure 6. Sanger Sequencing Showing
Allelic Imbalance in Mutation Carriers
from Families 1 and 3
(A) Allelic imbalance in blood from
affected subject (IV-29) and unaffected
carrier (II-11) from family 1 using SNP
rs448475 as a marker.
(B) Allelic imbalance in saliva from affected
carrier (II-3) from family 3 using rs2229992
as a marker.which are transcribed. We could detect expression only of
the wild-type allele and not the mutant transcript in these
samples (Figure S11).Discussion
We identified three point mutations in the promoter 1B of
APC that perfectly segregate with GAPPS in all six families,
including one (family 1) with 27 affected individuals
(Figure 1). These mutations were missed in the WES and
Hi-seq WGS we performed in these families, either because
the enrichment kits did not capture the promoter 1B or
because of poor coverage (4-11X), but were identified by
Complete Genomics, X Ten, and Sanger sequencing. All
three mutations were located in a YY1 binding motif, dis-
rupting the affinity of YY1 for the APC promoter 1B and
were found to show reduced transcriptional activity in re-
porter assays in gastric and colorectal cancer cell lines. In
carriers from family 1, we observed allelic imbalance of
APC in blood, stomach, and FGPs, suggesting that the pres-
ence of these mutations leads to decreased allele-specific
expression in vivo. Allelic imbalance was also observed in
an affected member of family 3 and in an affected carrier
of the c.190G>A mutation from a FAP-affected family.
YY1 is a ubiquitously expressed transcription factor that
has been shown to have multiple roles in oncogenesis
and can act as both an activator and repressor of transcrip-
tion.60 Here we show that it acts as a transcription factor
regulating expression of APC IB promoter transcripts.
We also observed a second hit in the majority of GAPPS
FGPs, either by loss of the wild-type allele or somatic pro-
tein truncatingmutations. However, despite using sections
composed of 75%–100% polyp cells for DNA isolation,
these events appeared to occur in only a small proportion
of cells. This suggests that they are late events in the gene-
sis of FGPs. We propose that APC haploinsufficiency is838 The American Journal of Human Genetics 98, 830–842, May 5, 2016responsible for the fundic gland pol-
yposis in GAPPS, and the second
APC hit might be the driver of
dysplasia.
Although the APC promoter 1B and
distal enhancer elements have not
been extensively studied, Hosoya
et al. estimated transcription from
the promoter 1B was 15-fold higherthan from the promoter 1A61 in gastric mucosa. Consistent
with this, the APC promoter 1A (but never promoter 1B)
was reported to be methylated in 100% of gastric cancer
cell lines, 97.5% of non-cancerous gastric mucosa, and
82.5% of primary gastric cancers.62 We also observed pro-
moter 1A methylation in GAPPS and sporadic FGPs and
in normal stomach. These studies suggest that 1B tran-
scripts are more important than 1A in gastric mucosa,
which might explain why all known GAPPS-affected fam-
ilies carry promoter 1Bmutations but only rare cases of FAP
(1/111; 0.9% W.D.F., unpublished data) carry similar vari-
ants, the colonic cells usually being protected by the
expression of the 1A isoform.63 Large (11–132 kb) dele-
tions that include all or some of the promoter 1B, as well
as additional sequences, have been observed in FAP46–50
(Figure 3), but we know of only two point mutations in
this region that result in FAP. These large deletions result
in allelic imbalance in the expression of both the 1A and
1B isoforms,47 perhaps because they delete enhancers of
the promoter 1A as well as the promoter 1B. This might
explain why point mutations in the promoter 1B rarely
seem to cause FAP. Although fundic gland polyposis has
not been consistently described in all the FAP families
with large deletions around the promoter 1B, it seems
more prevalent than in FAP families with mutations
within the APC gene.47,48,64
The APC 1B isoform is in-frame with the 1A isoform but
encodes a slightly different protein, which differs at the
N terminus by the inclusion of exon 1B and also lacks
two alternate in-frame exons (exons 2 and 7; Figure 3).
The most common mutations in FAP are nonsense muta-
tions and small deletions in APC, which result in the
expression of a truncated protein65 that might have a
dominant-negative, or gain-of-function, effect at least in
the colon.27,66,67 Truncating mutations occurring outside
of exons 2 and 7 would be expected to have the same effect
on the 1B isoform, and indeed fundic gland polyposis
occurs in about 50% of individuals with AFAP or FAP. We
have found that there is no difference in the presence of
FGPs between individuals who have mutations within
exons 2 and 7, consistent with an AFAP phenotype, versus
those withmutations outside this region, consistent with a
classic FAP phenotype (D.W.N., unpublished data). Point
mutations in promoters have been observed in other can-
cer predisposition syndromes,68,69 but only once before
in the APC 1B promoter.55 Our finding that GAPPS is
caused by point mutations in the promoter 1B of APC,
and the description of gastric polyposis and gastric cancer
in some individuals with large deletions around the pro-
moter 1B,46–50 would suggest that families with alterations
in the promoter 1B are at risk of gastric adenocarcinoma,
regardless of whether colorectal polyps are or are not pre-
sent. Conversely, most observations to date indicate low
risk for colonic polyposis and cancer in GAPPS, but recog-
nition that GAPPS is due to a variant in the same gene that
causes FAP suggests that GAPPS exists along the pheno-
typic spectrum of FAP, thus broadening the understanding
of the disease spectrum caused by APC aberrations. There-
fore, in small GAPPS-affected families in which there has
been little opportunity to observe the family’s phenotype,
it might be prudent to undertake colonoscopic surveil-
lance to characterize a family’s colon phenotype with a
plan for reassessment dictated by the findings. In carriers
of these point mutations in the YY1 binding site of the pro-
moter 1B, penetrance of the gastric polyposis phenotype is
high, though not complete, with variable phenotype
ranging from asymptomatic adults to teenagers presenting
with massive symptomatic gastric polyposis. Figure 1
shows five unaffected carriers who had clean endoscopies
at ages ranging from 42 to 77. However, the penetrance
for gastric cancer is less clear becausemany of themutation
carriers in family 1 have had prophylactic gastrectomies,
often in their 20s. In summary, our data show that specific
point mutations in the YY1 binding site in the promoter
1B of APC are the cause of GAPPS, a new and potentially
severe variant of FAP.Accession Numbers
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